{"DataElement":{"publicId":"6842068","version":"1","preferredName":"Nivolumab Total Infusion Administered Count","preferredDefinition":"The total number of Nivolumab infusions administered to the patient.","longName":"NIVO_INFSN_TOTAL_CT","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"6841900","version":"1","preferredName":"Nivolumab Total Infusion Method of Administration Administered","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._The technique of administration of a pharmaceutical product, usually slowly and in larger volumes than for an injection, by introducing it into the body, usually after puncturing the skin; it is usually administered intravenously, but occasionally by other routes, e.g. subcutaneously._The act of having given something (e.g., a medication or test).","longName":"4882031v1.0:6842064v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"4882031","version":"1","preferredName":"Nivolumab","preferredDefinition":"A fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.","longName":"C68814","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18D28FE9-699E-68CC-E050-BB89AD437B6D","latestVersionIndicator":"Yes","beginDate":"2015-06-18","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-06-18","modifiedBy":"ONEDATA","dateModified":"2015-06-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6842064","version":"1","preferredName":"Total Infusion Method of Administration Administered","preferredDefinition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition.:The technique of administration of a pharmaceutical product, usually slowly and in larger volumes than for an injection, by introducing it into the body, usually after puncturing the skin; it is usually administered intravenously, but occasionally by other routes, e.g. subcutaneously.:The act of having given something (e.g., a medication or test).","longName":"C25304:C149577:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total","conceptCode":"C25304","definition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Infusion Method of Administration","conceptCode":"C149577","definition":"The technique of administration of a pharmaceutical product, usually slowly and in larger volumes than for an injection, by introducing it into the body, usually after puncturing the skin; it is usually administered intravenously, but occasionally by other routes, e.g. subcutaneously.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F130096-4378-3D07-E053-F662850AD1B2","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"ONEDATA","dateModified":"2019-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F130096-42FB-3D07-E053-F662850AD1B2","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"TSESU","dateModified":"2022-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018392","version":"1","preferredName":"Count","preferredDefinition":"The quantity of the specified item.","longName":"CT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261845","version":"1","preferredName":"Count","preferredDefinition":"To determine the number or amount of something; the result of this activity.","longName":"C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FBB87F7A-646B-1AFC-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-13","modifiedBy":"ONEDATA","dateModified":"2005-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B3BF4389-4489-5F2C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-09","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-01-08","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/11/17 tt transferred context, added reg status and CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280726","version":"1","longName":"Evaluations","context":"ABTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Total Number of Infusions: Ni","type":"Preferred Question Text","description":"Total Number of Infusions: Nivolumab","url":null,"context":"ABTC"}],"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F134498-C7F3-44A6-E053-F662850A6F70","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"TSESU","dateModified":"2022-07-07","changeDescription":"8/1/19 - smt Created for ABTC 1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}